Cardiovascular SAEs reported over 2 years of follow-up were assessed in 5 golimumab phase 3 clinical trials of patients with rheumatoid arthritis ( GO-BEFORE , GO-FORWARD , and GO-AFTER ) , psoriatic arthritis ( GO-REVEAL ) , and ankylosing spondylitis ( GO-RAISE ) .